JP4460829B2 - 妊娠関連血漿蛋白−ａ２（ｐａｐｐ−ａ２） - Google Patents

妊娠関連血漿蛋白−ａ２（ｐａｐｐ−ａ２） Download PDF

Info

Publication number
JP4460829B2
JP4460829B2 JP2002536334A JP2002536334A JP4460829B2 JP 4460829 B2 JP4460829 B2 JP 4460829B2 JP 2002536334 A JP2002536334 A JP 2002536334A JP 2002536334 A JP2002536334 A JP 2002536334A JP 4460829 B2 JP4460829 B2 JP 4460829B2
Authority
JP
Japan
Prior art keywords
papp
polypeptide
sequence
amino acid
igfbp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002536334A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004511253A (ja
JP2004511253A5 (enExample
Inventor
クラウス・オクスヴィッヒ
ミカエル・トフト・オーヴァーゴード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Como Biotech ApS
Original Assignee
Como Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Como Biotech ApS filed Critical Como Biotech ApS
Publication of JP2004511253A publication Critical patent/JP2004511253A/ja
Publication of JP2004511253A5 publication Critical patent/JP2004511253A5/ja
Application granted granted Critical
Publication of JP4460829B2 publication Critical patent/JP4460829B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
JP2002536334A 2000-10-20 2001-10-19 妊娠関連血漿蛋白−ａ２（ｐａｐｐ−ａ２） Expired - Fee Related JP4460829B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24184000P 2000-10-20 2000-10-20
DKPA200001571 2000-10-20
PCT/DK2001/000695 WO2002032953A2 (en) 2000-10-20 2001-10-19 Pregnancy-associated plasma protein-a2 (papp-a2)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009291514A Division JP5072950B2 (ja) 2000-10-20 2009-12-22 妊娠関連血漿蛋白−ａ２（ｐａｐｐ−ａ２）

Publications (3)

Publication Number Publication Date
JP2004511253A JP2004511253A (ja) 2004-04-15
JP2004511253A5 JP2004511253A5 (enExample) 2007-07-05
JP4460829B2 true JP4460829B2 (ja) 2010-05-12

Family

ID=44063430

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002536334A Expired - Fee Related JP4460829B2 (ja) 2000-10-20 2001-10-19 妊娠関連血漿蛋白−ａ２（ｐａｐｐ−ａ２）
JP2009291514A Expired - Fee Related JP5072950B2 (ja) 2000-10-20 2009-12-22 妊娠関連血漿蛋白−ａ２（ｐａｐｐ−ａ２）
JP2012147230A Pending JP2012229235A (ja) 2000-10-20 2012-06-29 妊娠関連血漿蛋白−ａ２（ｐａｐｐ−ａ２）

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009291514A Expired - Fee Related JP5072950B2 (ja) 2000-10-20 2009-12-22 妊娠関連血漿蛋白−ａ２（ｐａｐｐ−ａ２）
JP2012147230A Pending JP2012229235A (ja) 2000-10-20 2012-06-29 妊娠関連血漿蛋白−ａ２（ｐａｐｐ−ａ２）

Country Status (6)

Country Link
US (6) US7083940B2 (enExample)
EP (2) EP2339020B1 (enExample)
JP (3) JP4460829B2 (enExample)
AU (1) AU2002210403A1 (enExample)
CA (2) CA2818654A1 (enExample)
WO (1) WO2002032953A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002210403A1 (en) * 2000-10-20 2002-04-29 Como Biotech Aps Pregnancy-associated plasma protein-a2 (papp-a2)
AT500321B1 (de) * 2003-12-30 2006-02-15 Red Bull Gmbh Verfahren zur diagnose des down-syndroms
CA2549066C (en) * 2004-01-28 2012-11-13 Turun Yliopisto Diagnosing acute coronary syndrome by measuring levels of free papp-a
US20050277147A1 (en) * 2004-06-11 2005-12-15 Ameet Patki Identifying chromosomal abnormalities in cells obtained from follicular fluid
US20060205651A1 (en) * 2005-02-25 2006-09-14 Royal College Of Surgeons In Ireland Method of treating cancer
EP2161347B1 (en) * 2005-03-18 2016-08-24 The Chinese University Of Hong Kong Markers for prenatal diagnosis and monitoring
US8653020B2 (en) * 2008-01-25 2014-02-18 Aarhus Universitet Selective exosite inhibition of PAPP-A activity against IGFBP-4
GB0910751D0 (en) 2009-06-23 2009-08-05 Procure Therapeutics Ltd Prostate cancer vaccine
US9532404B2 (en) * 2010-04-28 2016-12-27 Watlow Electric Manufacturing Company Flow through heater
WO2011144999A1 (en) * 2010-05-17 2011-11-24 Sandra Reznik Plasma protein-a2 (papp-a2) as a marker for detecting risk of chromosomal abnormalities
CA2886489A1 (en) * 2011-10-14 2013-04-18 Aarhus Universitet Diagnostic and prognostic use of prombp-complexes
US10670610B2 (en) 2012-06-15 2020-06-02 Wayne State University Biomarker test for prediction or early detection of preeclampsia and/or HELLP syndrome
WO2014036440A2 (en) * 2012-08-30 2014-03-06 Ansh Labs Llc Papp-a2 as a marker for monitoring, predicting and diagnosing preeclampsia
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10543259B2 (en) * 2015-03-02 2020-01-28 Children's Hospital Medical Center Methods and compositions for the identification and treatment of individuals having or likely to develop short stature
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN110194801B (zh) * 2018-02-26 2022-06-14 张灏 一种融合蛋白和多克隆抗体及其应用
US11988674B2 (en) 2018-08-07 2024-05-21 University Of South Carolina Methods for measuring gene expression levels to identify viable oocytes
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
TW202432584A (zh) * 2022-11-15 2024-08-16 美商嘉來克生命科學有限責任公司 抗papp-a抗體及其使用方法
TW202528331A (zh) * 2023-11-13 2025-07-16 美商嘉來克生命科學有限責任公司 關於基於肽之ｐａｐｐ－ａ調節劑之組合物及方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI83662C (fi) * 1980-07-17 1991-08-12 Scripps Clinic Res Diagnostik antikropp och foerfarande foer dess framstaellning.
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
GB9614615D0 (en) 1996-07-11 1996-09-04 Isis Innovation Diagnosis of pre-eclampsia
US6432628B1 (en) * 1997-08-26 2002-08-13 Thomas Jefferson University Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use
JP2002538804A (ja) * 1999-03-15 2002-11-19 オヴェルガルド，ミッチェル，トフト インスリン様増殖因子結合タンパク質−４プロテアーゼ
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US6656700B2 (en) 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
WO2001095855A2 (de) * 2000-06-16 2001-12-20 Harald Tschesche Pregnancy-associated plasma-protein-e (papp-e)
AU2002210403A1 (en) 2000-10-20 2002-04-29 Como Biotech Aps Pregnancy-associated plasma protein-a2 (papp-a2)
US6500630B2 (en) * 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
EP1910569A4 (en) * 2005-06-17 2009-08-05 Genizon Biosciences Inc GENEMAP GENE CARD OF HUMAN GENES ASSOCIATED WITH LONGEVITY
US20080071151A1 (en) * 2006-06-30 2008-03-20 Sogin David C Method and Apparatus for Diagnosing Pre-eclampsia
ES2523220T3 (es) * 2008-01-25 2014-11-24 Perkinelmer Health Sciences, Inc. Métodos para determinar el riesgo de complicaciones prenatales

Also Published As

Publication number Publication date
US9005949B2 (en) 2015-04-14
CA2464121A1 (en) 2002-04-25
US7083940B2 (en) 2006-08-01
US20150132770A1 (en) 2015-05-14
US20070141669A1 (en) 2007-06-21
JP2004511253A (ja) 2004-04-15
WO2002032953A3 (en) 2003-01-09
WO2002032953A2 (en) 2002-04-25
US10392610B2 (en) 2019-08-27
AU2002210403A1 (en) 2002-04-29
CA2464121C (en) 2013-08-13
JP2012229235A (ja) 2012-11-22
US20130095569A1 (en) 2013-04-18
US20030124529A1 (en) 2003-07-03
JP5072950B2 (ja) 2012-11-14
EP1346061B1 (en) 2014-12-17
EP2339020A1 (en) 2011-06-29
CA2818654A1 (en) 2002-04-25
US20110091920A1 (en) 2011-04-21
EP1346061A2 (en) 2003-09-24
EP2339020B1 (en) 2017-03-08
JP2010222341A (ja) 2010-10-07
US20130095482A1 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
JP5072950B2 (ja) 妊娠関連血漿蛋白−ａ２（ｐａｐｐ−ａ２）
AU2009200138B2 (en) Use of insulin-like growth binding protein-4 protease
WO2001032920A2 (en) Agents implicated in endometriosis
KR100884487B1 (ko) 인자 ⅶ-활성화 프로테아제의 돌연변이체 및 특이적 항체를 포함하는 진단학적 조성물
US20100136014A1 (en) GIPs, a Family of Polypeptides with Transcription Factor Activity that Interact with Goodpasture Antigen Binding Protein
JP2002517253A (ja) セリンプロテアーゼであるコリン
US7115382B1 (en) Method for detecting IGFBP-4 protease without detecting IGFBP-4 protease/proMBP Complex
US6790622B2 (en) Tumor suppressor encoding nucleic acid, PTX1, and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070220

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070227

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20070521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070823

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20070823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070904

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20070904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081215

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090928

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091021

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091130

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100121

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100215

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4460829

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130219

Year of fee payment: 3

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130219

Year of fee payment: 3

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140219

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees